Cellectis: Preclinical Data on CAR T-cells to Enhance Efficacy Targeting Triple Negative Breast Cancer at AACR

  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today released preclinical data on TALEN^®-edited MUC1 CAR T-cells at the American Association for Cancer Research (AACR) Annual Meeting 2023. The data showed the capability of armored allogeneic MUC1 CAR T-cells to excel in the immune suppressive tumor micro-environment suggesting that they could be an effective option in treating relapsed and refractory triple negative breast cancer (TNBC) patients with limited therapeutic options.

Tumor-associated MUC1 antigen is overexpressed in a large number of TNBC patients offering an effective discriminatory target for CAR T-cell therapy.

Cellectis’ MUC1 CAR T-cells are allogeneic and target Mucin 1 for TNBC and a variety of epithelial cancers. As other solid tumor targets can be plagued by safety concerns due to off-tumor expression, MUC1 is of high interest as its expression in normal epithelium is restricted to apical membranes. Additionally, MUC1 heavy glycosylation in normal tissue contrasts with Cellectis’ MUC1 CAR that is designed to recognize hypoglycosylated MUC1 present in cancer cells. Cellectis’ MUC1 CAR T-cells incorporate up to four TALEN^®-mediated knockouts and two knock-ins.

https://www.biospace.com/article/releases/cellectis-presents-preclinical-data-on-talen-edited-muc1-car-t-cells-to-enhance-efficacy-in-targeting-triple-negative-breast-cancer-at-the-american-association-for-cancer-research-aacr-annual-meeting/